135 related articles for article (PubMed ID: 11886387)
1. Outbreak of vancomycin-resistant Enterococcus faecium in a haematology unit: risk factor assessment and successful control of the epidemic.
Timmers GJ; van der Zwet WC; Simoons-Smit IM; Savelkoul PH; Meester HH; Vandenbroucke-Grauls CM; Huijgens PC
Br J Haematol; 2002 Mar; 116(4):826-33. PubMed ID: 11886387
[TBL] [Abstract][Full Text] [Related]
2. Treatment options for vancomycin-resistant enterococcal infections.
Linden PK
Drugs; 2002; 62(3):425-41. PubMed ID: 11827558
[TBL] [Abstract][Full Text] [Related]
3. 2004 Lowbury Lecture: the Western Australian experience with vancomycin-resistant enterococci - from disaster to ongoing control.
Pearman JW
J Hosp Infect; 2006 May; 63(1):14-26. PubMed ID: 16563562
[TBL] [Abstract][Full Text] [Related]
4. Treatment of vancomycin-resistant Enterococcus faecium infections.
Lai KK
Arch Intern Med; 1996 Dec 9-23; 156(22):2579-84. PubMed ID: 8951301
[TBL] [Abstract][Full Text] [Related]
5. Genotyping and preemptive isolation to control an outbreak of vancomycin-resistant Enterococcus faecium.
Mascini EM; Troelstra A; Beitsma M; Blok HE; Jalink KP; Hopmans TE; Fluit AC; Hene RJ; Willems RJ; Verhoef J; Bonten MJ
Clin Infect Dis; 2006 Mar; 42(6):739-46. PubMed ID: 16477546
[TBL] [Abstract][Full Text] [Related]
6. Role of environmental contamination as a risk factor for acquisition of vancomycin-resistant enterococci in patients treated in a medical intensive care unit.
MartÃnez JA; Ruthazer R; Hansjosten K; Barefoot L; Snydman DR
Arch Intern Med; 2003 Sep; 163(16):1905-12. PubMed ID: 12963563
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for colonization with vancomycin-resistant enterococci in a Melbourne hospital.
MacIntyre CR; Empson M; Boardman C; Sindhusake D; Lokan J; Brown GV
Infect Control Hosp Epidemiol; 2001 Oct; 22(10):624-9. PubMed ID: 11776348
[TBL] [Abstract][Full Text] [Related]
8. Outbreak of vancomycin resistant enterococcus in a hematology/oncology unit in a Korean University Hospital, and risk factors related to patients, staff, hospital care and facilities.
Oh HS; Kim EC; Oh MD; Choe KW
Scand J Infect Dis; 2004; 36(11-12):790-4. PubMed ID: 15764162
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment of vancomycin-resistant Enterococcus faecium bacteremia with linezolid after failure of treatment with synercid (quinupristin/dalfopristin).
McNeil SA; Clark NM; Chandrasekar PH; Kauffman CA
Clin Infect Dis; 2000 Feb; 30(2):403-4. PubMed ID: 10671355
[No Abstract] [Full Text] [Related]
10. Vancomycin-resistant Enterococcus faecium osteomyelitis: successful treatment with quinupristin-dalfopristin.
Summers M; Misenhimer GR; Antony SJ
South Med J; 2001 Mar; 94(3):353-5. PubMed ID: 11284529
[TBL] [Abstract][Full Text] [Related]
11. Recommendations for the successful control of a large outbreak of vancomycin-resistant Enterococcus faecium in a non-endemic hospital setting.
Frakking FNJ; Bril WS; Sinnige JC; Klooster JEV; de Jong BAW; van Hannen EJ; Tersmette M
J Hosp Infect; 2018 Dec; 100(4):e216-e225. PubMed ID: 29475013
[TBL] [Abstract][Full Text] [Related]
12. Quinupristin-dalfopristin versus linezolid for the treatment of vancomycin-resistant Enterococcus faecium bacteraemia: efficacy and development of resistance.
Chong YP; Lee SO; Song EH; Lee EJ; Jang EY; Kim SH; Choi SH; Kim MN; Jeong JY; Woo JH; Kim YS
Scand J Infect Dis; 2010 Jul; 42(6-7):491-9. PubMed ID: 20524781
[TBL] [Abstract][Full Text] [Related]
13. Treatment of vancomycin-resistant enterococcus with quinupristin/dalfopristin and high-dose ampicillin.
Bethea JA; Walko CM; Targos PA
Ann Pharmacother; 2004 Jun; 38(6):989-91. PubMed ID: 15100393
[TBL] [Abstract][Full Text] [Related]
14. Quinupristin/Dalfopristin therapy for infections due to vancomycin-resistant Enterococcus faecium.
Winston DJ; Emmanouilides C; Kroeber A; Hindler J; Bruckner DA; Territo MC; Busuttil RW
Clin Infect Dis; 2000 May; 30(5):790-7. PubMed ID: 10817685
[TBL] [Abstract][Full Text] [Related]
15. Vancomycin-resistant Enterococcus.
Thierfelder C; Keller PM; Kocher C; Gaudenz R; Hombach M; Bloemberg GV; Ruef C
Swiss Med Wkly; 2012; 142():w13540. PubMed ID: 22618895
[TBL] [Abstract][Full Text] [Related]
16. Outbreak of vancomycin-resistant enterococci in a burn unit.
Falk PS; Winnike J; Woodmansee C; Desai M; Mayhall CG
Infect Control Hosp Epidemiol; 2000 Sep; 21(9):575-82. PubMed ID: 11001260
[TBL] [Abstract][Full Text] [Related]
17. Outcomes for and risk factors associated with vancomycin-resistant Enterococcus faecalis and vancomycin-resistant Enterococcus faecium bacteremia in cancer patients.
Ghanem G; Hachem R; Jiang Y; Chemaly RF; Raad I
Infect Control Hosp Epidemiol; 2007 Sep; 28(9):1054-9. PubMed ID: 17932826
[TBL] [Abstract][Full Text] [Related]
18. Impact of the more-potent antibiotics quinupristin-dalfopristin and linezolid on outcome measure of patients with vancomycin-resistant Enterococcus bacteremia.
Erlandson KM; Sun J; Iwen PC; Rupp ME
Clin Infect Dis; 2008 Jan; 46(1):30-6. PubMed ID: 18171210
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. Synercid Emergency-Use Study Group.
Moellering RC; Linden PK; Reinhardt J; Blumberg EA; Bompart F; Talbot GH
J Antimicrob Chemother; 1999 Aug; 44(2):251-61. PubMed ID: 10473233
[TBL] [Abstract][Full Text] [Related]
20. Hospital-acquired infection with vancomycin-resistant Enterococcus faecium transmitted by electronic thermometers.
Livornese LL; Dias S; Samel C; Romanowski B; Taylor S; May P; Pitsakis P; Woods G; Kaye D; Levison ME
Ann Intern Med; 1992 Jul; 117(2):112-6. PubMed ID: 1605425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
